30 results about "Bone Marrow-Derived Cell" patented technology

This invention provides pharmaceutical compositions and methods related to the prevention and treatment of primary tumors and metastatic, malignant or spreading cancers by selectively targeting cancer associated myeloid derived cells by the targeted delivery of a bisphosphonate formulated with a non-liposomal particle carrier. In some aspects, the bisphosphonate particles have one or more properties suitable for phagocytosis by cancer associated myeloid derived cells and release of the bisphosphonate within the macrophages. Advantageously, administering the particles to a subject reduces the level and/or activity of cancer associated myeloid derived cells in the subject.

The present inventors revealed the following for the first time in the world:

• 1) a large amount of bone marrow-derived cells are mobilized to grafted skin;
• 2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow derived cells include bone marrow-derived mesenchymal stem cells;
• 3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin;
• 4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow;
• 5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart;
• 6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and
• 7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that:

(1) a large number of bone marrow-derived cells are mobilized to grafted skin;

(2) mobilized bone marrow-derived cells differentiate into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in grafted skin, and thus mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;

(3) S100A8 and S100A9 released from necrotic tissues of grafted skin are responsible for mobilizing bone marrow-derived mesenchymal stem cells to the grafted skin from peripheral blood; and

(4) purified S100A8 and S100A9 promote the migration of mesenchymal stem cells isolated/cultured from the bone marrow.

Insulin-producing bone marrow derived stem cells, and methods of generating and using same to reduce blood glucose levels in individuals.

The invention provides a preparation method of a medical cartilage support material. The preparation method comprises the following operation steps of: pretreatment, separation and primary washing of a cartilage tissue, inactivation of virus, decellularization, sodium chloride treatment, forming, and packaging and sterilization. The bone marrow-derived cell component and DNA (Deoxyribonucleic Acid) component of an animal are completely removed from the medical cartilage support material prepared by the method, meanwhile a natural ECM (Extracellular Cell Matrix) component and a three-dimensional are completely remained, and no endotoxin, organic solvent and toxic solvent are left; the medical cartilage support material has a porosity suitable for cell ingrowth and cartilage tissue regeneration, and also has ideal mechanical properties.

This invention provides a method of rapid and adequate culture of cells isolated from a body to effectively construct bone/cartilage tissues and implants containing the bone/cartilage tissues constructed by the aforementioned method. In this method, osteo-/chondro-inducible transcription factor genes are transfected into bone-marrow-derived cells isolated from a body using an adenoviral or a retroviral vector to grow on adequate scaffolds. The constructed bone/cartilage tissues are transplanted into a body together with the scaffolds. Thus, they can be used as substitutional bone/cartilage implants.

The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell.

The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein.

Isolated recombinant cells and a pharmaceutical composition are also provided.

This invention provides alternative bone implants that have high bioadaptability and enable rapid bone regeneration. Specifically, this invention relates to implants consisting of a bioadaptable material comprising cells transfected with growth factor genes. Such implants are produced by inoculating bone-marrow-derived cells transfected with the genes of vascular endothelial growth factors (VEGF) into a bioadaptable material, such as porous ceramics, and culturing them.

The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof.

The objects of the present invention are to solve low test efficiency and low accuracy which are problems encountered in the conventional methods for testing myelotoxicity of a drug by observing smears. To this end, markers for discriminating and identifying hematopoietic stem cells and blood cells at various differentiation stages in bone marrow are identified. From this point of view, cell surface antigens are specified. Thus, it is found that the myelotoxicity of a drug can be evaluated with a high efficiency at a high accuracy by using flow cytometry to analyze for a change in the quantity of bone marrow-derived cells expressing the cell surface antigens after administration of the drug to an animal.

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells to prior levels.

A method of treating neurological deficit in which the brain area affected is focally and precisely stimulated by the transient insertion and subsequent removal of a micro-needle. This insertion and subsequent removal of the micro-needle induces endogenous stem cells to proliferate, migrate and promote the brain's self-repair mechanisms. The micro-needle stimulation causes the birth of new neural cells within the brain as well as mobilizes bone marrow derived cells with a neuronal phenotype to migrate to the site of stimulation to repair and replace damaged neural cells. By repairing and/or replacing injured or dead cells, this approach will slow down the degenerative course of the disease and may result in reversal of symptoms.

Methods are provided for enhancing capacity of impaired bone marrow cells to promote angiogenesis when introduced into an ischemic site in a patient by transfecting early attaching cells derived from bone marrow in culture with an angiogenesis promoting transgene. Methods are also provided for utilizing such early attaching cells derived from autologous bone marrow, or media derived from these cells while the cells are grown in culture (which need not be from autologous cells) to deliver angiogenesis-promoting transgenes or proteins to a patient. The transfected early attaching cells, or media derived from these cells while the cells are grown in culture, are introduced into an ischemic tissue, such as the heart, to enhance formation of collateral blood vessels. The cells or media can also be injected into the blood stream (artery supplying the ischemic tissue, or any other artery or vein).

[Problems to be Solved] An objective of the present invention is to provide methods for regenerating or repairing damaged tissues using adrenomedullin. Another objective is to provide pharmaceutical agents that comprise adrenomedullin as an active ingredient for regenerating or repairing damaged tissues.

[Means for Solving the Problems] To solve the above problems, the present inventors administered adrenomedullin (hereinafter indicated as AM) or physiological saline to C57BL/6 mice, and counted the numbers of mononuclear cells and Sca-1-positive cells in the blood. The result showed that AM increased the numbers of mononuclear cells and stem cell antigen-1-positive cells in the blood. It was also shown that by administering AM to a mouse model of pulmonary emphysema and a rat model of acute myocardial infarction, the quantity of bone marrow-derived cells that migrated and settled into the damaged tissues increased, and the recruited bone marrow cells differentiated into blood vessels, alveoli, and cardiac muscle at the lesion sites. Further, decrease in infarct size, suppression of the enlargement of alveolar diameter, and improvement of organ functions were confirmed in the models of myocardial infarction and pulmonary emphysema.

The present invention is based on the findings that bone marrow (BM)-derived progenitor cells more specifically mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and uncommitted hematopoietic cells (lin⁻) are capable of regenerating liver in case of injury. The invention provides a method for treating genetic disorder like Alpha1-antitrypsin deficiency (A1-ATD) by administering BM derived Lin⁻ cells in human mutant A1-AT expressing transgenic mouse model. The invention also provides the state of art for replacement of mutant host hepatocytes by transplanting wild-type uncommitted donor (lin⁻) cells.

A method of using an estrogen receptor agonist and antagonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system. The methods comprise contacting the cells with a therapeutically effective amount of an estrogen receptor agonist or antagonist, and contacting the cells with a cytostatic agent, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced. Agonists disclosed include 17-beta-estradiol. Antagonists disclosed include antisense nucleic acids and selective estrogen receptor modulators (SERMs). Furthermore, uses and medicaments comprising estrogen receptor agonists and antagonists are provided, as are screening methods for identifying therapeutic candidates for reducing the effect of cytostatic agents, and methods of using estrogen receptor agonists for increasing the proliferation of CD117⁺ cells in a biological system.

Disclosed herein is a reprogrammed endothelial progenitor cell, said cell comprises a bone marrow-derived cell expressing the CD34+ marker and at least one cardiomyocyte-specific gene, as well as methods for preparing and using the same for cardiac regenerative medicine.